Current Report Filing (8-k)
June 08 2023 - 2:38PM
Edgar (US Regulatory)
0001642159
false
0001642159
2023-06-08
2023-06-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 8, 2023
SIGYN
THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware |
|
000-55575 |
|
47-2573116 |
(State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
2468
Historic Decatur Road
Suite
140
San
Diego, California
92106
(Address
of Principal Executive Offices) (Zip Code)
619-368-2000
(Registrant’s
Telephone Number, Including Area Code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
none |
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01 Other Events
On
July 15, 2022, the Company entered into an Original Issue Discount Senior Convertible Debenture due July 15, 2023 in the amount of $16,500
with an investor with a conversion price of $.50 per share. On June 2, 2023 the holder of this debenture converted it into 33,000 shares
of Common Stock at the contractual exercise price of $.50 per share.
During
the three months ended March 31, 2023, the Company entered into Original Issue Discount Senior Convertible Debentures totaling $970,200
aggregate principal amount of Note due in various dates in January through March 2024. The conversion price for the principal in connection
with voluntary conversions by the holders of these convertible debentures is $0.15 per share.
On
June 2, 2023, the holder of $181,500 of these Debentures were converted at the contractual exercise price of $0.15 resulting in the issuance
of 1,210,000 shares of Common Stock to the holder.
As
a result of these issuances the number of outstanding shares of the Company has increased from 42,981,659 to 44,224,659.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
June 8, 2023
|
SIGYN
THERAPEUTICS, INC. |
|
|
|
By: |
/s/
Jim Joyce |
|
Name: |
Jim
Joyce |
|
Title: |
CEO |
Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sigyn Therapeutics (QB) (USOTC:SIGY)
Historical Stock Chart
From Aug 2023 to Aug 2024